Pegaspargase
- Generic Name
- Pegaspargase
- Brand Names
- Oncaspar
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 130167-69-0
- Unique Ingredient Identifier
- 7D96IR0PPM
- Background
Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synt...
- Indication
Pegaspargase is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with 1) first-line acute lymphoblastic leukemia or 2) acute lymphoblastic leukemia and hypersensitivity to asparaginase.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL)
- Associated Therapies
- -
Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: prednisoneDrug: vincristine sulfateDrug: daunorubicin hydrochlorideDrug: asparaginaseDrug: methotrexateDrug: cyclophosphamideDrug: cytarabineDrug: mercaptopurineDrug: leucovorin calciumDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: thioguanineRadiation: radiation therapyDrug: pegaspargaseOther: pharmacological studyDrug: nelarabineOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT00016302
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Biological: filgrastimDrug: asparaginaseDrug: cyclophosphamideDrug: cyclosporineDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: etoposideDrug: ifosfamideDrug: imatinib mesylateDrug: leucovorin calciumDrug: mercaptopurine tabletDrug: methotrexateDrug: pegaspargaseDrug: vincristine sulfateProcedure: allogeneic bone marrow transplantationProcedure: peripheral blood stem cell transplantationProcedure: umbilical cord blood transplantationRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 220
- Registration Number
- NCT00022737
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1076
- Registration Number
- NCT00005596
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Floating Hospital for Children, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 838
- Registration Number
- NCT00005585
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
🇺🇸Floating Hospital for Children, Boston, Massachusetts, United States
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
- Conditions
- Interventions
- Biological: dactinomycinBiological: sargramostimDrug: carmustineDrug: cyclophosphamideDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: doxorubicin hydrochlorideDrug: methotrexateDrug: etoposideDrug: mercaptopurineDrug: prednisoneDrug: mitoxantrone hydrochlorideDrug: pegaspargaseDrug: vincristine sulfateRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 170
- Registration Number
- NCT00002766
- Locations
- 🇺🇸
Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 3054
- Registration Number
- NCT00005945
- Locations
- 🇺🇸
Medical City Dallas Hospital, Dallas, Texas, United States
🇺🇸Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸MD Anderson Cancer Center at University of Texas, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.